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Background: Some hemodialysis patients require large doses of erythropoiesis-stimulating agents (ESAs) to
manage anemia. These patients, termed “ESA hyporesponsive,” have been characterized using various definitions.
We applied three definitions of hyporesponsiveness to a large, national cohort of hemodialysis patients to assess
the impact of definition on counts and on characteristics associated with hyporesponsiveness.
Methods: We studied point-prevalent hemodialysis patients on May 1, 2008, with Medicare as primary payer, who
survived through December 31, 2008. Included patients received recombinant human erythropoietin (EPO) in each
month, August-December. Hyporesponsiveness definitions were: above the ninetieth percentile of total monthly
EPO dose; above the ninetieth percentile of total monthly EPO dose divided by weight in kg; above the ninetieth
percentile of total monthly EPO dose divided by hemoglobin level. Hyporesponsiveness was further classified as
chronic, acute, or other. Comorbid conditions were assessed before and concurrent with the hyporesponsive period.
Results: Women, African Americans, and patients aged <40 years, with cause of renal failure other than diabetes or
hypertension, or longer dialysis duration, were more likely to be hyporesponsive. Antecedent comorbid conditions
most predictive of any subsequent hyporesponsiveness were congestive heart failure, peripheral vascular disease, other
cardiac disease, gastrointestinal bleeding, and cancer. Concurrent comorbid conditions most strongly associated with
any hyporesponsiveness were gastrointestinal bleeding and cancer. All conditions were somewhat more likely when
ascertained concurrently. Comorbidity burdens were lowest for non-hyporesponsive patients.
Conclusions: As associations were similar between patient characteristics and three methods of characterizing EPO
hyporesponsiveness, the simplest definition using EPO dose can be used.
Keywords: Epidemiology, Epoetin, HemodialysisBackground
Endogenous erythropoietin production is greatly reduced
for patients receiving maintenance hemodialysis, who
generally require regular administration of exogenous
erythropoietin or transfusions. A subset of these patients
receive very large doses of erythropoiesis-stimulating agents
(ESAs) as part of a strategy for anemia management.
The term “ESA hyporesponsive” has been used to refer
to patients who need high doses of ESAs to increase and
maintain their hemoglobin levels. This phenomenon is* Correspondence: dgilbertson@cdrg.org
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distribution, and reproduction in any mediumgenerally believed to be due to a variety of factors,
including absolute or functional iron deficiency and
inflammation. Patients can experience short-term acute
episodes of hyporesponsiveness, or longer more chronic
episodes. There does not appear to be a standardized def-
inition of ESA hyporesponsiveness. However, a number
of studies have investigated various aspects of hypo-
responsiveness, using a variety of definitions and produ-
cing different estimates of proportions of hyporesponsive
patients and factors associated with hyporesponsiveness.
Management of anemia is expensive for these patients,
and interest in increasing treatment effectiveness and effi-
ciency is growing, particularly with the January 2011 im-
plementation of the new Medicare dialysis reimbursementtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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investigate different definitions of ESA hyporesponsiveness
and their associations with patient characteristics. We
applied three different definitions of hyporesponsiveness
to the same large, national cohort of hemodialysis patients
to assess the impact of definition on counts and on patient
characteristics associated with hyporesponsiveness.
Methods
Subjects and measurements
We studied point prevalent in-center and home hemo-
dialysis patients on May 1, 2008, with Medicare as primary
payer, who survived through December 31, 2008. Included
patients received recombinant human erythropoietin (EPO)
in each month, August through December. Figure 1
displays the time periods used in the study. The months
August through December were used to characterize
hyporesponsiveness and comorbidity concurrent with the
hyporesponsiveness period. The months May through
July were used to characterize comorbidity prior to the
hyporesponsive period (antecedent period).
Three different definitions of hyporesponsiveness were
applied to each of the 5 months:
1. Above the ninetieth percentile of total monthly
EPO dose.
2. Above the ninetieth percentile of total monthly EPO
dose divided by patient weight in kg.
3. Above the ninetieth percentile of total monthly EPO
dose divided by patient hemoglobin level (also known
as the EPO resistance index).
Definition 2 acknowledges that EPO dosing may depend
on patient weight, and definition 3 considers a measure
that has been used in other studies to assess issues related
to hyporesponsiveness. Table 1 displays the distributions
for these definitions. As an example, using total monthly
EPO dose, a patient whose total dose was greater than
176,400 units (the ninetieth percentile) was considered








Figure 1 Study time periods. The months August through December we
concurrent with the hyporesponsiveness period. The months May through
hyporesponsive period (antecedent period).hyporesponsive category for at least 1 of the 5 months
was considered hyporesponsive. Next, considering all
5 months for each patient, hyporesponsive patients were
further classified as chronic (hyporesponsive in ≥ 4 con-
secutive months), acute (hyporesponsive in ≤ 3 consecu-
tive months and not hyporesponsive for at least 1 month
before and 1 month after the hyporesponsive months),
or other (neither the chronic nor the acute definition
applied).
Comorbid conditions assessed during the antecedent
period were atherosclerotic heart disease, congestive heart
failure (CHF), cerebrovascular accident/transient ischemic
attack, peripheral vascular disease (PVD), other cardiac
disease, chronic obstructive pulmonary disease, gastro-
intestinal bleeding, liver disease, dysrhythmia, cancer, and
diabetes. These conditions were again assessed during the
concurrent period. We also characterized age, sex, race,
cause of renal failure, dialysis duration, average body mass
index during the concurrent period, vascular access
complications, intravenous (IV) antibiotic use, number of
hospital admissions, number of hospitalization days, infec-
tious hospitalizations, profit status of dialysis provider, and
region of the country. Both antecedent and concurrent
comorbid conditions were defined from Medicare Part A
and Part B claims, using a method previously validated
for diabetes [1]. This method uses International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
diagnosis codes, and requires at least one inpatient,
home health, or skilled nursing facility claim with a
qualifying diagnosis, or at least two physician/supplier
or hospital outpatient claims with a qualifying diagnosis,
to define the condition.
Analysis
Descriptive statistics for categorical variables (count [n],
percent) were used to examine patient demographic
characteristics and comorbid conditions according to
hyporesponsiveness definition (total EPO dose, EPO dose/
weight in kg, EPO dose/hemoglobin level) and category
(chronic, acute, other). Logistic regression was used toDec 31, 2008 
siveness: any ≥ 4 consecutive months
siveness: ≤ 3 consecutive months,




re used to characterize hyporesponsiveness and comorbidity
July were used to characterize comorbidity prior to the
Table 1 Distributions of hyporesponsiveness definitions*
Percentile
Hyporesponsiveness definition Minimum 10th 20th 50th 80th 90th Maximum
Monthly EPO dose 500.0 13,800.0 22,100.0 52,000.0 116,000.0 176,400.0 728,000.0
Monthly EPO dose/patient weight in kg 3.4 180.1 291.4 677.1 1534.8 2346.7 476,666.7
Resistance index† 34.0 1140.7 1869.2 4442.3 10,361.9 16,252.3 111,815.5
EPO, erythropoietin.
*Monthly erythropoietin dose, monthly erythropoietin dose divided by patient weight in kilograms, and monthly erythropoietin dose divided by patient
hemoglobin level.
†Monthly EPO dose divided by patient hemoglobin level.
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sponsiveness (chronic, acute, and other). SAS, version 9.1
(SAS Institute Inc., Cary, North Carolina) was used for
data analysis.
Ethics statement
This study was performed with the approval of the
Hennepin County Medical Center (Minneapolis, Minnesota)
institutional review board.
Results
The study included 138,688 patients. Patient characteristics
were similar to the overall Medicare prevalent hemodialysis
population: 52% male, 42% African American, 48% aged
≥ 65 years, 45% with diabetes as cause of renal failure,
and 42% with dialysis duration < 3 years.
Table 2 shows the hyporesponsiveness categories
obtained using total EPO dose to define monthly hypo-
responsiveness, by patient characteristics. The categories
are chronic (hyporesponsive for ≥ 4 consecutive months),
acute (hyporesponsive for ≤ 3 consecutive months with at
least 1 non-hyporesponsive month before and after), and
other (some patterns of monthly hyporesponsiveness fit
neither the chronic nor the acute categories). Of patients
with any hyporesponsiveness, 23%, 26%, and 51% were
classified as chronic, acute, or other, respectively. To
determine how to classify the “other” group, the squared
error for each row of Table 2 was calculated, other
compared with chronic, and other compared with acute.
The square root of the sum of these values (a measure of
distance) confirms that the “other” category is most simi-
lar to the acute category (distance = 43.6 for other/
chronic, distance = 12.0 for other/acute); therefore, other
and acute were grouped into a “non-chronic” category for
further analyses. Distance was also assessed using the
other 2 definitions of hyporesponsiveness, with similar
findings (not shown).
Table 3 shows the three definitions of hyporesponsiveness,
and within each the categories of non-hyporesponsive,
chronic, and non-chronic. A similar number of patients
were classified as non-hyporesponsive, chronic, and non-
chronic by each of the three definitions, and a comparison
of patient characteristics showed no major differences.Men were more likely than women to be chronically
hyporesponsive; African Americans were more likely than
whites or members of other races to be hyporesponsive
generally (chronic and non-chronic). Younger patients
were more likely to be hyporesponsive generally, and
patients whose cause of renal failure was other than
diabetes or hypertension were more likely to be chron-
ically hyporesponsive. Comparing comorbid conditions,
all were somewhat more likely when ascertained concur-
rently with hyporesponsiveness than when ascertained
in the antecedent period. Comorbidity burdens were
lowest for non-hyporesponsive patients. Comparing chronic
with non-chronic hyporesponsiveness with respect to
comorbid conditions, levels of comorbidity were generally
slightly higher for patients classified with non-chronic
hyporesponsiveness, particularly when comorbidity was
assessed concurrently with the hyporesponsive period.
Patients receiving IV antibiotics were more likely to be
classified with non-chronic hyporesponsiveness, as were
patients with three or more hospitalizations.
Table 4 shows adjusted odds ratios for any hypore-
sponsiveness compared with none. Two of the three
methods showed similar results: total EPO dose and EPO
dose divided by hemoglobin level (resistance index).
Women, African Americans, and patients aged < 40 years,
with cause of renal failure other than diabetes or hyper-
tension, or longer dialysis duration, were more likely to be
hyporesponsive. The antecedent comorbid conditions
most predictive of any subsequent hyporesponsiveness
were CHF, PVD, other cardiac disease, gastrointestinal
bleeding, and cancer. Of concurrent comorbid conditions,
associations with any hyporesponsiveness were strongest
for gastrointestinal bleeding and cancer. Results of EPO
dose per kg of body weight were somewhat different
with respect to odds ratios for weight and sex; this is
not surprising, since in this model, weight would be
expected to be a strong predictor of EPO dose divided
by weight. The term for sex is also affected since weight
is correlated with sex.
Discussion
We found very similar associations between patient
characteristics and three methods of characterizing EPO
Table 2 Hyporesponsiveness categories for total erythropoietin dose
Hyporesponsiveness Squared difference
All None Chronic Acute Other Other - chronic Other - acute
n 138,688 111,422 6248 7219 13,799
Sex
Men 51.8 51.6 54.7 51.0 52.5 4.9 2.3
Women 48.2 48.4 45.3 49.0 47.5
Race
White 51.4 52.6 46.2 47.4 46.0 0.1 1.8
African American 42.2 40.5 49.8 47.5 49.5 0.1 4.1
Other 6.4 6.9 3.9 5.1 4.4
Age, years
< 40 8.1 7.5 12.9 9.8 10.3 7.0 0.2
40-64 44.3 42.7 54.9 48.3 50.3 20.6 4.1
65-74 24.9 25.5 19.8 24.5 22.8 9.3 2.9
≥ 75 22.7 24.4 12.5 17.4 16.6
Cause of renal failure
Diabetes 44.9 45.3 38.7 45.7 44.1 29.0 2.8
Hypertension 29.3 29.6 27.8 27.8 28.8 1.0 1.1
Glomerulonephritis 10.2 10.0 12.2 10.3 10.7 2.2 0.1
Cystic kidney disease 2.2 2.2 2.1 2.0 1.8 0.1 0.1
Other 13.5 13.0 19.3 14.2 14.7
Dialysis duration, years
< 1 9.6 9.8 7.7 9.4 8.6 0.9 0.5
1 to < 3 32.6 33.5 26.3 31.3 28.9 6.7 5.8
3 to < 5 23.6 23.6 23.2 23.0 23.8 0.3 0.7
≥ 5 34.3 33.1 42.8 36.4 38.7
Average BMI, kg/m2
< 18.5 3.7 3.6 3.3 4.3 3.8 0.2 0.3
≥ 18.5 and < 25 34.9 35.2 30.4 36.5 33.5 9.4 8.8
≥ 25 and < 30 28.5 28.9 25.6 27.6 27.3 2.8 0.1
≥ 30 33.0 32.3 40.7 31.6 35.4
Antecedent comorbid conditions
ASHD 22.0 20.4 26.0 29.8 28.5 6.3 1.6
CHF 19.6 17.2 29.9 29.7 28.8 1.3 0.8
CVA/TIA 7.4 6.9 7.5 10.9 9.6 4.0 1.9
PVD 16.5 14.8 23.1 24.2 23.3 0.1 0.9
Other cardiac disease 12.4 10.6 20.3 20.0 19.2 1.1 0.6
COPD 8.4 7.3 13.2 12.7 12.9 0.1 0.0
GI bleeding 3.3 2.5 7.2 6.1 6.1 1.2 0.0
Liver disease 5.5 5.2 7.4 6.3 6.8 0.3 0.3
Dysrhythmia 13.7 12.4 19.1 19.2 18.8 0.0 0.1
Cancer 4.1 3.6 7.2 5.3 5.8 2.1 0.2
Diabetes 49.7 48.9 49.2 55.0 53.0 14.1 4.1
Concurrent comorbid conditions
ASHD 30.1 28.4 32.9 41.2 37.0 16.8 17.3
CHF 27.6 24.6 38.9 42.9 39.1 0.0 14.7
CVA/TIA 10.9 10.2 10.5 16.9 13.5 9.3 11.3
PVD 24.8 22.8 30.3 35.8 32.7 5.6 10.0
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Table 2 Hyporesponsiveness categories for total erythropoietin dose (Continued)
Other cardiac disease 19.7 17.2 28.3 32.4 28.8 0.3 12.5
COPD 12.5 11.1 18.2 19.2 17.9 0.1 1.6
GI bleeding 5.3 4.1 10.6 11.2 9.6 1.0 2.7
Liver disease 6.4 6.0 8.9 7.8 8.0 0.9 0.0
Dysrhythmia 19.8 18.1 25.1 28.4 26.4 1.8 3.9
Cancer 5.6 5.0 9.9 7.2 7.6 5.5 0.1
Diabetes 57.3 56.7 55.6 62.1 60.2 20.8 3.7
Number of vascular access complication
0 61.9 61.9 64.0 55.4 53.7 106.1 2.7
1-3 19.9 19.9 19.1 21.7 23.4 17.8 2.7
≥ 4 18.2 18.2 16.9 22.9 22.9
Average iron dose per month, mg
Non-users 15.1 16.2 13.0 9.5 10.4 7.1 0.7
< 233 21.1 23.0 11.4 14.6 13.9 6.6 0.5
≥ 233 and < 360 21.1 21.5 16.6 20.2 20.1 12.0 0.0
≥ 360 and < 460 20.9 20.5 20.9 23.9 22.5 2.5 2.0
≥ 460 21.8 18.8 38.1 31.8 33.2 24.5 1.9
IV antibiotic use
No 76.9 76.9 79.6 65.6 66.6 168.0 1.0
Yes 23.1 23.1 20.5 34.4 33.4
Number of hospital admissions
0 63.3 63.3 68.3 45.7 44.8 549.0 0.8
1 20.8 20.8 19.4 26.7 26.0 43.2 0.5
≥ 2 15.9 15.9 12.3 27.6 29.2
Number of hospitalization days
0 63.3 63.3 68.3 45.7 44.8 549.0 0.8
1-7 18.4 18.4 17.3 24.4 22.4 25.6 4.2
≥ 8 18.4 18.4 14.4 29.8 32.8
Infectious hospitalizations
No 88.2 88.2 90.6 80.3 79.2 129.8 1.2
Yes 11.8 11.8 9.4 19.7 20.8
Dialysis provider
Non-profit 14.0 14.0 14.7 12.4 11.0 13.0 1.7
For profit 85.0 85.0 84.4 86.5 87.6 9.8 1.1
Unknown 1.0 1.0 0.9 1.1 1.4
Region
Northeast 15.7 15.7 15.7 15.0 15.1 0.4 0.0
Midwest 19.1 19.1 19.4 19.0 17.8 2.6 1.5
South 45.2 45.2 43.7 50.8 51.9 67.9 1.2
West 17.2 17.2 18.3 12.6 12.6 33.1 0.0
Unknown 2.8 2.8 2.9 2.7 2.7
Distance – – – – – 43.6 12.0
ASHD, atherosclerotic heart disease; BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular
accident/transient ischemic attack; GI, gastrointestinal; IV, intravenous; PVD, peripheral vascular disease.
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of body weight, or EPO dose per hemoglobin level).
Given this finding, using the simplest of the three
methods we investigated, total EPO dose, to characterizehyporesponsiveness seems justifiable. Our findings re-
lating hyporesponsiveness to patient characteristics
are largely in agreement with other studies in other
populations that used different methods to characterize
Table 3 The three definitions of hyporesponsiveness
Monthly EPO dose Monthly EPO dose/patient weight
in kg
Resistance index*
Hyporesponsiveness type None Chronic Non-
chronic
Any None Chronic Non-
chronic
Any None Chronic Non-
chronic
Any
n 111,422 6248 21,018 27,266 110,767 5905 22,016 27,921 110,022 5761 22,905 28,666
Sex
Men 51.6 54.7 52.0 52.6 52.9 48.3 47.3 47.5 51.6 55.0 51.7 52.4
Women 48.4 45.3 48.0 47.4 47.1 51.7 52.7 52.5 48.4 45.0 48.3 47.6
Race
White 52.6 46.2 46.5 46.4 52.5 45.8 47.2 46.9 52.6 46.4 46.7 46.6
African American 40.5 49.8 48.8 49.1 40.9 48.4 46.7 47.0 40.5 49.6 48.4 48.6
Other 6.9 3.9 4.7 4.5 6.5 5.9 6.2 6.1 6.9 4.0 4.9 4.7
Age, years
< 40 7.5 12.9 10.1 10.7 7.5 13.7 9.8 10.6 7.4 13.3 10.1 10.7
40 to 64 42.7 54.9 49.6 50.8 43.7 49.2 45.8 46.5 42.7 54.8 49.2 50.3
65 to 74 25.5 19.8 23.4 22.6 25.3 20.5 23.8 23.1 25.4 19.4 23.7 22.8
≥ 75 24.4 12.5 16.9 15.9 23.5 16.6 20.5 19.7 24.5 12.5 17.0 16.1
Cause of renal failure
Diabetes 45.3 38.7 44.6 43.3 46.3 32.4 41.3 39.4 45.3 38.3 44.5 43.3
Hypertension 29.6 27.8 28.4 28.3 29.2 29.6 29.9 29.8 29.6 27.7 28.5 28.3
Glomerulonephritis 10.0 12.2 10.6 10.9 9.9 13.2 10.8 11.3 10.2 10.0 12.1 10.5
Cystic kidney disease 2.2 2.1 1.9 1.9 2.2 2.2 2.1 2.1 2.2 2.2 2.1 2.1
Other 13.0 19.3 14.5 15.6 12.5 22.6 16.0 17.4 13.5 12.9 19.8 14.4
Dialysis duration, years
< 1 9.8 7.7 8.9 8.6 9.8 7.5 8.8 8.5 9.8 7.9 8.9 8.7
1 to < 3 33.5 26.3 29.7 29.0 33.9 24.2 28.6 27.7 33.5 26.4 30.0 29.3
3 to < 5 23.6 23.2 23.5 23.4 23.8 21.2 23.1 22.7 23.6 22.9 23.5 23.4
≥ 5 33.1 42.8 37.9 39.0 32.5 47.0 39.5 41.1 33.1 42.9 37.5 38.6
Average BMI, kg/m2
< 18.5 3.6 3.3 4.0 3.8 2.8 8.3 6.9 7.2 3.6 3.5 4.1 4.0
≥ 18.5 and < 25 35.2 30.4 34.5 33.6 32.2 47.2 44.7 45.2 35.1 31.1 34.8 34.1
≥ 25 and < 30 28.9 25.6 27.4 27.0 29.2 25.1 26.2 26.0 28.9 25.9 27.2 26.9
≥ 30 32.3 40.7 34.1 35.6 35.8 19.4 22.1 21.5 32.4 39.5 33.9 35.0
Antecedent comorbid conditions
ASHD 20.4 26.0 29.0 28.3 20.3 26.8 29.1 28.6 20.3 25.9 28.7 28.1
CHF 17.2 29.9 29.1 29.3 17.0 30.7 29.6 29.8 17.1 29.9 28.8 29.0
CVA/TIA 6.9 7.5 10.0 9.5 6.7 8.7 10.5 10.1 6.9 7.6 9.9 9.4
PVD 14.8 23.1 23.6 23.5 14.9 22.7 23.3 23.2 14.8 23.4 23.3 23.3
Other cardiac disease 10.6 20.3 19.5 19.7 10.4 21.8 20.0 20.4 10.6 20.4 19.0 19.3
COPD 7.3 13.2 12.8 12.9 7.2 13.6 12.9 13.0 7.3 13.4 12.6 12.8
GI bleeding 2.5 7.2 6.1 6.4 2.4 8.0 6.4 6.7 2.5 7.6 6.1 6.4
Liver disease 5.2 7.4 6.6 6.8 5.2 7.7 6.5 6.8 5.2 7.6 6.6 6.8
Dysrhythmia 12.4 19.1 19.0 19.0 12.2 20.0 19.1 19.3 12.4 19.3 18.6 18.7
Cancer 3.6 7.2 5.6 6.0 3.5 8.0 5.6 6.1 3.6 7.6 5.5 5.9
Diabetes 48.9 49.2 53.6 52.6 49.8 43.6 50.4 49.0 48.9 49.3 53.6 52.7
Concurrent comorbid conditions
ASHD 28.4 32.9 38.4 37.2 28.3 33.6 38.4 37.4 28.3 33.2 38.4 37.3
CHF 24.6 38.9 40.4 40.1 24.3 40.2 40.9 40.7 24.4 39.9 40.0 40.0
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Table 3 The three definitions of hyporesponsiveness (Continued)
CVA/TIA 10.2 10.5 14.6 13.7 9.9 11.9 15.5 14.7 10.1 10.7 14.6 13.8
PVD 22.8 30.3 33.7 32.9 22.8 30.5 33.6 32.9 22.6 31.1 33.7 33.2
Other cardiac disease 17.2 28.3 30.0 29.6 16.9 30.9 30.6 30.7 17.0 29.2 29.9 29.8
COPD 11.1 18.2 18.4 18.3 11.0 18.1 18.5 18.4 11.0 19.1 18.2 18.4
GI bleeding 4.1 10.6 10.1 10.2 4.0 11.9 10.2 10.6 4.0 11.4 10.2 10.4
Liver disease 6.0 8.9 7.9 8.1 5.9 9.4 7.9 8.2 6.0 9.3 7.7 8.0
Dysrhythmia 18.1 25.1 27.1 26.6 18.0 26.8 27.1 27.0 18.0 25.8 26.8 26.6
Cancer 5.0 9.9 7.4 8.0 4.9 10.6 7.8 8.4 5.0 10.5 7.4 8.0
Diabetes 56.7 55.6 60.8 59.6 57.7 49.3 57.5 55.8 56.6 55.5 60.8 59.7
Number of vascular access complication
0 61.9 64.0 53.0 55.5 63.7 56.1 54.5 54.8 64.2 55.1 53.0 53.4
1-3 19.9 19.1 23.3 22.4 19.2 21.9 22.7 22.5 19.1 21.8 23.2 22.9
≥ 4 18.2 16.9 23.7 22.1 17.0 22.0 22.9 22.7 16.7 23.1 23.8 23.7
Average iron dose per month, mg
Non-users 16.2 13.0 10.1 10.7 16.0 14.2 11.1 11.8 16.2 13.5 10.4 11.0
< 233 23.0 11.4 14.2 13.5 22.9 12.4 14.9 14.3 23.1 11.4 14.4 13.8
≥ 233 and < 360 21.5 16.6 20.1 19.3 21.5 17.1 20.2 19.5 21.5 16.4 20.3 19.5
≥ 360 and < 460 20.5 20.9 22.9 22.5 20.6 20.7 22.3 21.9 20.6 20.4 22.5 22.1
≥ 460 18.8 38.1 32.7 34.0 19.1 35.5 31.6 32.4 18.7 38.3 32.4 33.6
IV antibiotic use
No 76.9 79.6 66.5 69.5 79.4 66.3 67.5 67.2 79.7 64.9 66.5 66.2
Yes 23.1 20.5 33.5 30.5 20.6 33.7 32.5 32.8 20.3 35.1 33.5 33.8
Number of hospital admissions
0 63.3 68.3 42.1 48.1 68.6 43.6 42.0 42.3 68.7 43.5 42.2 42.5
1 20.8 19.4 26.4 24.8 19.4 26.2 26.7 26.6 19.3 26.7 26.7 26.7
≥ 2 15.9 12.3 31.5 27.1 12.1 30.2 31.4 31.1 12.0 29.8 31.2 30.9
Number of hospitalization days
0 63.3 68.3 42.1 48.1 68.6 43.6 42.0 42.3 68.7 43.5 42.2 42.5
1-7 18.4 17.3 22.1 21.0 17.3 23.8 22.2 22.5 17.2 24.1 22.4 22.7
≥ 8 18.4 14.4 35.8 30.9 14.1 32.6 35.8 35.1 14.1 32.4 35.4 34.8
Infectious hospitalizations
No 88.2 90.6 78.0 80.9 90.7 79.1 78.2 78.4 90.8 78.9 78.3 78.4
Yes 11.8 9.4 22.0 19.1 9.3 20.9 21.8 21.6 9.2 21.1 21.7 21.6
Dialysis provider
Non-profit 14.0 14.7 11.2 12.0 14.6 13.0 11.6 11.9 14.6 12.5 11.7 11.9
For profit 85.0 84.4 87.5 86.8 84.5 85.8 87.1 86.8 84.5 86.4 87.0 86.9
Unknown 1.0 0.9 1.3 1.2 0.9 1.2 1.3 1.3 0.9 1.2 1.3 1.3
Region
Northeast 15.7 15.7 15.4 15.5 15.6 15.6 15.9 15.8 15.8 15.3 15.3 15.3
Midwest 19.1 19.4 17.5 17.9 19.5 17.5 17.2 17.3 19.4 19.0 17.8 18.0
South 45.2 43.7 51.7 49.8 44.0 49.4 50.3 50.1 43.7 50.2 51.4 51.2
West 17.2 18.3 12.9 14.2 18.0 14.8 14.1 14.2 18.3 12.9 13.1 13.1
Unknown 2.8 2.9 2.5 2.6 2.9 2.9 2.4 2.5 2.9 2.6 2.5 2.5
ASHD, atherosclerotic heart disease; BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular
accident/transient ischemic attack; EPO, erythropoietin; GI, gastrointestinal; IV, intravenous; PVD, peripheral vascular disease.
*Monthly EPO dose divided by patient hemoglobin level.
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Table 4 Adjusted odds ratios for hyporesponsiveness
Monthly EPO dose Monthly EPO dose/patient weight in kg Resistance index*
Odds ratio (95% CI) P Odds ratio (95% CI) Odds ratio (95% CI) P
Sex
Men 1.00 1.00 1.00
Women 1.08 (1.04-1.11) < 0.0001 1.49 (1.44-1.54) < 0.0001 1.08 (1.05-1.11) < 0.0001
Race
White 1.00 1.00 1.00
African American 1.11 (1.07-1.15) < 0.0001 1.07 (1.03-1.11) < 0.0001 1.10 (1.06-1.14) < 0.0001
Other 1.01 (0.94-1.08) 0.89 1.22 (1.15-1.30) < 0.0001 1.04 (0.97-1.12) 0.23
Age- years
< 40 1.00 1.00 1.00
40 to 64 0.87 (0.82-0.92) < 0.0001 0.85 (0.81-0.90) < 0.0001 0.86 (0.81-0.91) < 0.0001
65 to 74 0.68 (0.64-0.73) < 0.0001 0.73 (0.68-0.77) < 0.0001 0.69 (0.65-0.73) < 0.0001
≥ 75 0.54 (0.51-0.58) < 0.0001 0.61 (0.57-0.65) < 0.0001 0.54 (0.51-0.57) < 0.0001
Cause of renal failure
Diabetes 1.00 1.00 1.00 s
Hypertension 1.11 (1.06-1.16) < 0.0001 1.12 (1.07-1.17) < 0.0001 1.12 (1.07-1.17) < 0.0001
Glomerulonephritis 1.20 (1.13-1.28) < 0.0001 1.18 (1.11-1.25) < 0.0001 1.22 (1.15-1.30) < 0.0001
Cystic kidney disease 1.05 (0.94-1.18) 0.3771 1.03 (0.93-1.15) 0.5768 1.07 (0.96-1.20) 0.2223
Other 1.40 (1.32-1.47) < 0.0001 1.44 (1.36-1.52) < 0.0001 1.40 (1.33-1.48) < 0.0001
Dialysis duration- years
< 1 1.00 1.00 1.00
1 to < 3 1.13 (1.06-1.19) < 0.0001 1.05 (0.99-1.11) 0.10 1.13 (1.07-1.19) < 0.0001
3 to < 5 1.36 (1.29-1.45) < 0.0001 1.28 (1.21-1.36) < 0.0001 1.34 (1.27-1.42) < 0.0001
≥ 5 1.60 (1.51-1.70) < 0.0001 1.57 (1.48-1.66) < 0.0001 1.56 (1.47-1.65) < 0.0001
Average BMI- kg/m2
< 18.5 1.00 1.00 1.00
≥ 18.5 and < 25 0.97 (0.90-1.05) 0.48 0.56 (0.52-0.60) < 0.0001 0.94 (0.87-1.02) 0.12
≥ 25 and < 30 0.99 (0.91-1.07) 0.73 0.35 (0.32-0.37) < 0.0001 0.94 (0.86-1.02) 0.12
≥ 30 1.05 (0.97-1.14) 0.23 0.20 (0.18-0.21) < 0.0001 0.99 (0.91-1.07) 0.79
Antecedent comorbid conditions
ASHD 1.08 (1.04-1.13) 0.0002 1.11 (1.06-1.15) < 0.0001 1.08 (1.04-1.13) 0.0002
CHF 1.23 (1.18-1.28) < 0.0001 1.24 (1.19-1.29) < 0.0001 1.24 (1.19-1.29) < 0.0001
CVA/TIA 1.05 (0.99-1.11) 0.09 1.07 (1.01-1.13) 0.02 1.05 (0.99-1.11) 0.12
PVD 1.25 (1.20-1.30) < 0.0001 1.21 (1.17-1.26) < 0.0001 1.24 (1.19-1.29) < 0.0001
Other cardiac disease 1.25 (1.20-1.31) < 0.0001 1.27 (1.21-1.32) < 0.0001 1.21 (1.16-1.26) < 0.0001
COPD 1.18 (1.12-1.25) < 0.0001 1.16 (1.10-1.23) < 0.0001 1.16 (1.10-1.23) < 0.0001
GI bleeding 1.51 (1.40-1.62) < 0.0001 1.62 (1.51-1.74) < 0.0001 1.56 (1.45-1.68) < 0.0001
Liver disease 1.17 (1.07-1.28) 0.00 1.13 (1.04-1.24) 0.01 1.19 (1.09-1.30) < 0.0001
Dysrhythmia 1.16 (1.10-1.21) < 0.0001 1.15 (1.09-1.20) < 0.0001 1.14 (1.09-1.19) < 0.0001
Cancer 1.45 (1.33-1.57) < 0.0001 1.36 (1.26-1.48) < 0.0001 1.43 (1.32-1.55) < 0.0001
Diabetes 1.07 (1.02-1.13) 0.00 1.06 (1.01-1.11) 0.02 1.09 (1.04-1.14) 0.00
Concurrent comorbid conditions
ASHD 0.94 (0.90-0.97) 0.00 0.93 (0.90-0.97) 0.00 0.94 (0.90-0.97) 0.00
CHF 1.12 (1.08-1.17) < 0.0001 1.14 (1.09-1.18) < 0.0001 1.10 (1.06-1.15) < 0.0001
CVA/TIA 0.94 (0.90-0.99) 0.02 0.99 (0.94-1.04) 0.59 0.94 (0.89-0.99) 0.01
PVD 1.02 (0.98-1.06) 0.25 1.03 (1.00-1.07) 0.08 1.03 (1.00-1.07) 0.09
Other cardiac disease 1.14 (1.10-1.18) < 0.0001 1.16 (1.12-1.20) < 0.0001 1.15 (1.10-1.19) < 0.0001
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Table 4 Adjusted odds ratios for hyporesponsiveness (Continued)
COPD 1.04 (0.99-1.09) 0.15 1.01 (0.96-1.06) 0.63 1.04 (1.00-1.09) 0.08
GI bleeding 1.45 (1.36-1.53) < 0.0001 1.44 (1.35-1.52) < 0.0001 1.50 (1.41-1.59) < 0.0001
Liver disease 1.05 (0.97-1.14) 0.24 1.09 (1.01-1.19) 0.03 1.01 (0.93-1.09) 0.86
Dysrhythmia 1.03 (0.98-1.07) 0.21 1.00 (0.96-1.04) 0.87 1.02 (0.98-1.07) 0.31
Cancer 1.32 (1.23-1.42) < 0.0001 1.36 (1.27-1.47) < 0.0001 1.32 (1.23-1.41) < 0.0001
Diabetes 1.02 (0.97-1.07) 0.38 0.98 (0.93-1.03) 0.39 1.02 (0.98-1.07) 0.35
Number of vascular access complication
0 1.00 1.00 1.00
1-3 1.10 (1.06-1.15) < 0.0001 1.07 (1.03-1.11) 0.0005 1.10 (1.06-1.14) < 0.0001
≥ 4 1.15 (1.10-1.20) < 0.0001 1.13 (1.08-1.17) < 0.0001 1.16 (1.11-1.21) < 0.0001
Average iron dose per month- mg
Non-users 1.00 1.00 1.00
< 233 1.00 (0.94-1.06) 0.9360 0.97 (0.92-1.03) 0.3598 0.97 (0.91-1.02) 0.2483
≥ 233 and < 360 1.31 (1.23-1.38) < 0.0001 1.25 (1.18-1.32) < 0.0001 1.28 (1.21-1.35) < 0.0001
≥ 360 and < 460 1.55 (1.47-1.64) < 0.0001 1.45 (1.38-1.53) < 0.0001 1.48 (1.40-1.56) < 0.0001
≥ 460 2.36 (2.24-2.50) < 0.0001 2.19 (2.07-2.31) < 0.0001 2.27 (2.15-2.39) < 0.0001
IV antibiotic use
No 1.00 1.00 1.00
Yes 1.26 (1.22-1.31) < 0.0001 1.26 (1.22-1.31) < 0.0001 1.26 (1.22-1.31) < 0.0001
Number of hospital admissions
0 1.00 1.00 1.00
1 1.49 (1.43-1.56) < 0.0001 1.51 (1.45-1.58) < 0.0001 1.54 (1.48-1.60) < 0.0001
≥ 2 1.88 (1.77-1.98) < 0.0001 1.91 (1.81-2.02) < 0.0001 1.95 (1.84-2.06) < 0.0001
Infectious hospitalizations
No 1.00 1.00 1.00
Yes 1.10 (1.05-1.15) < 0.0001 1.13 (1.08-1.18) < 0.0001 1.10 (1.05-1.15) < 0.0001
Dialysis provider
Non-profit 1.00 1.00 1.00
For profit 1.19 (1.10-1.28) < 0.0001 1.19 (1.10-1.28) < 0.0001 1.18 (1.09-1.27) < 0.0001
Unknown 1.56 (1.33-1.83) < 0.0001 1.57 (1.34-1.85) < 0.0001 1.49 (1.27-1.75) < 0.0001
Region
Northeast 1.00 1.00 1.00
Midwest 0.89 (0.85-0.94) < 0.0001 0.88 (0.84-0.93) < 0.0001 0.92 (0.87-0.97) 0.0013
South 1.16 (1.11-1.21) < 0.0001 1.14 (1.09-1.19) < 0.0001 1.17 (1.12-1.23) < 0.0001
West 0.80 (0.75-0.84) < 0.0001 0.83 (0.79-0.88) < 0.0001 0.81 (0.77-0.86) < 0.0001
Unknown 0.91 (0.82-1.00) 0.0576 0.90 (0.82-1.00) 0.0401 0.88 (0.80-0.97) 0.0116
ASHD, atherosclerotic heart disease; BMI, body mass index; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease;
CVA/TIA, cerebrovascular accident/transient ischemic attack; EPO, erythropoietin; GI, gastrointestinal; IV, intravenous; PVD, peripheral vascular disease.
*Monthly EPO dose divided by patient hemoglobin level.
Gilbertson et al. BMC Nephrology 2013, 14:44 Page 9 of 11
http://www.biomedcentral.com/1471-2369/14/44hyporesponsiveness. With respect to the proportion of
patients classified as hyporesponsive, our definitions
produced approximately 20%, 4.5%, and 15% of patients
with any, chronic, and non-chronic hyporesponsiveness,
respectively. Other studies have not separated chronic
from non-chronic hyporesponsiveness. Attalah et al [2]
found that 17.6% of patients were hyporesponsive, defined
as requiring > 450 U/kg/week IV EPO, with average3-month hemoglobin < 11 g/dL, ferritin ≥ 500 ng/mL,
and TSAT ≤ 50%. Johnson et al [3] describe approximately
5% to 10% of patients as hyporesponsive, defined as
requiring > 450 U/kg/week IV EPO.
Potential causes of hyporesponsiveness have been
previously investigated and described, with varying levels
of supporting evidence [3-9]. Causes include absolute or
functional iron deficiency, inflammation, infection, lack
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nutritional factor deficiencies, aluminum overload, pure
red cell aplasia, malignancy, bone marrow disorders,
myelosuppressive agent use, and use of angiotensin
converting enzyme inhibitors and angiotensin receptor
blockers.
Using data from a large dialysis organization, Kalantar-
Zadeh et al [10] examined predictors of hyporesponsiveness.
Although they used a measure of hyporesponsiveness
different from ours (fitting hemoglobin trajectories to
individuals with mixed models), and their primary focus
was on iron markers and osteodystrophy, their findings
were similar with respect to age, sex, race, and major
comorbid conditions, including cancer, CHF, and dia-
betes. One notable difference was with respect to dialy-
sis duration; we found increasing hyporesponsiveness
with longer dialysis duration, compared with their
findings of decreased hyporesponsiveness. This may be
due to the particular categorization of dialysis duration
analyzed. The first 6 months after dialysis initiation, and
in particular, the first 3 months, is a period of high risk.
The mortality hazard appears to be highest shortly
after initiation, and decreases during the first 6 months.
Correspondingly, dialysis duration beyond 5 years shows
further increasing risk, as patients continue to accumulate
comorbidity. Therefore, investigation of hyporesponsiveness
associations within the first year, and beyond 5 years,
may be important for further study.
In another study by Kalantar-Zadeh et al [11], the
authors found associations between inflammatory markers
and hyporesponsiveness. We did not have access to data
on inflammatory markers; however, our findings of higher
comorbidity burden, higher number of vascular access
complications, and IV antibiotic use are in general agree-
ment with the earlier findings, since inflammatory burden
generally increases with these factors.
Limitations of the current study include lack of laboratory
data; somewhat arbitrary definitions of hyporesponsiveness
based on the ninetieth percentile of total monthly EPO
dose, dose/kg, or dose/hemoglobin level; possible misclassi-
fication of comorbid conditions due to use of claims to
identify them; lack of data on catheter use, which is known
to be associated with increased risk of infection and
inflammation; and residual confounding, which may
explain some of the adjusted logistic regression findings.
With respect to laboratory data, some definitions of
hyporesponsiveness in the literature have included infor-
mation on ferritin and TSAT; these data were not available
in our study. Despite these unavailable data, our findings
are generally similar to findings of other studies. Another
limitation is that knowledge of the distribution of
hemoglobin levels in a similar, large population is needed
to define a ninetieth percentile. Simply examining the
distribution in a small population (for example, at aparticular dialysis facility) to find the appropriate cut
point, which may not include any hyporesponsive
individuals, would not be appropriate.
A potential limitation involves the 2008 timeframe
of the data. This period is after release of CHOIR [12]
and CREATE [13] study results, which produced a
change in ESA dosing and hemoglobin levels, and before
implementation of the Medicare reimbursement bundle,
which may cause further declines in ESA doses and
hemoglobin levels. However, use of the ninetieth percent-
ile cut would still identify patients receiving the highest
10% of doses, given the overall population dosing levels at
a point in time.
Conclusions
Associations were similar between patient characteristics/
comorbidity and three methods of characterizing EPO
hyporesponsiveness. Results using the simplest of the three
methods (ninetieth percentile of EPO dose) were also
largely similar to other studies, suggesting the utility of the
simple method for characterizing hyporesponsiveness. With
implementation of the Medicare dialysis reimbursement
bundle in January 2011, which includes all injectables, the
previous financial incentive to use higher doses of ESAs will
be reversed. Anemia management strategies regarding the
relative use of ESAs and IV iron therapy may change as a
result of this, and how it will affect ESA hyporesponsiveness
is unknown. Future studies should continue to investigate
this area as anemia management changes in response to
the bundle.
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